Benzinga - Feed Your Mind.

Market Overview

UPDATE: Peregrine Says Preliminary Data From Phase II Study Shows Antiviral Activity and Positive Safety Profile at Both Bavituximab Doses Evaluated

Eddie Staley, Benzinga Staff Writer

December 29, 2011 9:02 AM

Tickers: PPHM

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted in: News, FDA

Partner Network

Around the Web, We're Loving...

Boston Bomb Probe Focuses on Bags and Pressure Cooker

Bank of America Falls On Q1 Results, Mortgage Settlement

What You Should Know About GOOG

Most Popular

Google Drive Goes Down, Halting Productivity for Many Users

Apple Broke Down - What do the Charts Say Now?

Coca-Cola Returning to a Franchise Model – With Conditions

Chipotle Mexican Grill Earnings Preview: Strong EPS, Sales Results Expected

iPad Mini Shipments May Fall 30%

Benzinga Market Primer: Wednesday, April 17

Related Articles (PPHM)

Peregrine Pharmaceuticals Hosts Annual Meeting; Highlights Bavituximab's Potential in Solid Tumor Therapy

Earnings Scheduled For March 12, 2013

UPDATE: Piper Jaffray Initiates Peregrine Pharmaceuticals with Overweight on Attractive Risk-Reward Opportunities

Peregrine Pharma Offers Update for Top-Line Data from Phase II Trial of Bavituximab

View the discussion thread.

Partner Network

Posts by Eddie Staley

Benzinga Professional

stats for benzinga